Catalyst Biosciences Inc (NASDAQ:CBIO) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price objective of $14.42 for the company and are forecasting that the company will post ($1.79) EPS for the current quarter, according to Zacks. Zacks has also given Catalyst Biosciences an industry rank of 110 out of 265 based on the ratings given to its competitors.

Several brokerages have commented on CBIO. B. Riley set a $19.00 price target on Catalyst Biosciences and gave the stock a “buy” rating in a research note on Monday. Zacks Investment Research upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Wednesday, November 8th.

Shares of Catalyst Biosciences (NASDAQ CBIO) traded up $2.95 during trading hours on Wednesday, reaching $12.91. The company’s stock had a trading volume of 1,348,073 shares, compared to its average volume of 463,862. Catalyst Biosciences has a 12 month low of $3.11 and a 12 month high of $18.88.

Hedge funds have recently bought and sold shares of the company. Virtu KCG Holdings LLC acquired a new stake in shares of Catalyst Biosciences in the second quarter valued at about $103,000. Bank of New York Mellon Corp purchased a new position in Catalyst Biosciences in the second quarter valued at about $107,000. Zacks Investment Management purchased a new position in Catalyst Biosciences in the second quarter valued at about $147,000. Vanguard Group Inc. boosted its holdings in Catalyst Biosciences by 294.1% in the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 32,621 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in Catalyst Biosciences in the second quarter valued at about $372,000. Institutional investors and hedge funds own 30.96% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Analysts Expect Catalyst Biosciences Inc (CBIO) to Post ($1.79) Earnings Per Share” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with's FREE daily email newsletter.